Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Technology, Consumer Services and Consumer Goods sectors propelled shares higher while losses in the...
By Sam Boughedda Investing.com — Shares of biotechnology firm Jasper Therapeutics (NASDAQ:JSPR) soared 112% after Oppenheimer analyst Jay Olson initiated coverage of the company with a...
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Telecoms, Technology and Healthcare sectors propelled shares lower. At the close in NYSE, the Dow Jones...
Shares of Amgen reached a 52-week low during trading today and at one point tested the $200 per share mark.
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Basic Materials, Healthcare and Consumer Goods sectors propelled shares higher. At the close in NYSE, the...
Amgen Inc (NASDAQ: AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study of Lumakras (sotorasib) for KRAS G12C-mutated cancers. Data will be presented at the...
Amgen's KRAS inhibitor Lumakras (sotorasib) showed promising results in two phase 1 trials when combined with other treatments.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc. (NASDAQ:...
Amgen Inc (NASDAQ: AMGN) and Neumora Therapeutics Inc have announced a strategic collaboration to advance neuroscience discovery, development, and commercialization. The companies will...
Amgen (AMGN) and Neumora Therapeutics announce a strategic collaboration to advance neuroscience discovery, development and commercialization.The companies will collaborate on...
Amgen (AMGN) and Kyowa Kirin (KYKOF) announce that positive data from a Phase 2 study of AMG 451/KHK4083 were presented at the 30th EADV Congress on Oct
The FDA has approved Amgen Inc's (NASDAQ: AMGN) Repatha (evolocumab) as an adjunct for pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to...
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Oil & Gas, Consumer Services and Financials sectors propelled shares higher while losses in the Healthcare,...
Thursday's top analyst upgrades and downgrades included Amgen, Biogen, Commscope, Lockheed Martin, Northrop Grumman, ONEOK, Plug Power and Roku.
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Oil & Gas, Financials and Consumer Services sectors propelled shares higher. At the close in NYSE, the...
Amgen (AMGN) announces that the U.S. District Court for the District of New Jersey has upheld patents that protect its psoriasis therapy Otezla (apremilast) in a patent...
Verastem Oncology (VSTM) announces a clinical collaboration agreement with Amgen (AMGN).VSTM up 22.5% premarket at $3.38; AMGN down 1%
Investing.com – U.S. equities were lower at the close on Friday, as losses in the Basic Materials, Utilities and Technology sectors propelled shares lower. At the close in NYSE, the Dow...
Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated advanced...
Amgen (AMGN) announces the first combination study results from Phase 1b/2 CodeBreaK 101 study in patients with KRAS G12C-mutated advanced colorectal cancer ((CRC)).These new data...
Amgen's medicine Lumakras was approved in Canada to treat certain patients with non-small cell lung cancer ((NSCLC)).Health Canada granted the approval to Lumakras (sotorasib)...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE: ABT) Adagio...
Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Healthcare, Telecoms and Utilities sectors propelled shares lower. At the close in NYSE, the Dow Jones...
Amgen Inc (NASDAQ: AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib). Lumakras, a KRASG12C inhibitor, is approved in the U.S. for...
Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Consumer Services, Technology and Basic Materials sectors propelled shares higher while losses in the...
Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication of respiratory disease. New...
Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
Johnson & Johnson (JNJ), Merck (MRK), and Amgen (AMGN) are trading ~0.6%, ~0.3%, and ~ 0.7% lower in the pre-market after Morgan Stanley made a series of changes to its...
Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Utilities, Consumer Goods and Consumer Services sectors propelled shares higher while losses in the Oil &...
Over the past month, Novo Nordisk (NVO), with a ~10.6% gain, dominated the large-cap healthcare companies engaged in drug development and manufacturing
Amgen Inc (NASDAQ: AMGN) has announced positive data from the HUYGENS Phase 3 study assessing if Repatha (evolocumab) could increase the thickness of the fibrous caps to improve a feature of...
Amgen (AMGN) announces positive data from the HUYGENS Phase 3 study showing that Repatha (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Oil & Gas, Financials and Industrials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Technology, Utilities and Consumer Services sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Healthcare, Utilities and Industrials sectors propelled shares higher while losses in the Oil & Gas, Basic...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about...
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Consumer Goods, Healthcare and Financials sectors propelled shares higher while losses in the Oil & Gas,...
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Basic Materials, Financials and Oil & Gas sectors propelled shares higher while losses in the Consumer Goods,...
California-based biotech Amgen (AMGN) boasts a recently FDA-approved drug called Lumakras, which was designed to treat adult patients with non-small cell lung cancer (NSCLC). “As we look to...
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Oil & Gas, Consumer Services and Financials sectors propelled shares higher. At the close in NYSE, the...
Amgen (AMGN) reported impressive second-quarter results but lowered its GAAP EPS guidance for the year. Total revenue was up 5% year-over-year to $6.5 billion, beating consensus estimates...
Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Technology, Utilities and Healthcare sectors propelled shares higher while losses in the Oil & Gas, Basic...
During the latest quarterly update, Amgen Inc (NASDAQ: AMGN) disclosed that it is resuming dosing for pavurutamab (AMG 710) but halted enrollment to a trial for AMG 427. Both were BiTE...
Amgen Inc (NASDAQ: AMGN) said it received notices from the IRS looking to increase its federal tax bill by $3.6 billion, plus interest, for 2010, 2011, and 2012. The company filed a...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Oil & Gas, Healthcare and Basic Materials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com - Amgen (NASDAQ:AMGN) reported on Tuesday second quarter {{erl-6466||earnings that beat analysts' forecasts and revenue that topped expectations. Amgen announced earnings per...
By Peter Nurse Investing.com - U.S. stocks are seen edging higher at the open Tuesday, with investors focusing on the corporate earnings season and the risk of slowing economic growth as...
By Geoffrey Smith Investing.com -- More local governments across the U.S. reintroduce mask mandates to stop the spread of Covid-19, while China's efforts to stop its own outbreak ratchet up...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
